Articles published by Agenus Inc.
Agenus to Participate in B. Riley Healthcare Conference
January 04, 2024
From Agenus Inc.
Via Business Wire
Tickers
AGEN
Botensilimab/Balstilimab Data in Neoadjuvant Colorectal Cancer Selected for ASCO-GI 2024
December 20, 2023
From Agenus Inc.
Via Business Wire
Tickers
AGEN
Agenus to Receive $25 Million Milestone Payment from Bristol Myers Squibb for TIGIT-CD96 Bispecific Program
December 11, 2023
From Agenus Inc.
Via Business Wire
Tickers
AGEN
Agenus Reports Third Quarter 2023 Results
November 07, 2023
From Agenus Inc.
Via Business Wire
Tickers
AGEN
Agenus Unveils New and Updated Botensilimab Data in Colorectal, Pancreatic, Lung, Melanoma, and Sarcoma
October 22, 2023
From Agenus Inc.
Via Business Wire
Tickers
AGEN
ESMO 2023: Agenus’ Botensilimab/Balstilimab Combination Delivers Durable Responses across Multiple Sarcoma Subtypes
October 21, 2023
From Agenus Inc.
Via Business Wire
Tickers
AGEN
Agenus To Host BOT/BAL Program Update at ESMO 2023
October 05, 2023
From Agenus Inc.
Via Business Wire
Tickers
AGEN
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 01, 2023
From Agenus Inc.
Via Business Wire
Tickers
AGEN
Agenus to Participate in September Investor Conferences
August 28, 2023
From Agenus Inc.
Via Business Wire
Tickers
AGEN
Agenus Prioritizes Resources to Accelerate Registration and Commercialization of BOT/BAL Program in Multiple Cancers
August 23, 2023
From Agenus Inc.
Via Business Wire
Tickers
AGEN
Agenus Reports Second Quarter 2023 Results
August 08, 2023
From Agenus Inc.
Via Business Wire
Tickers
AGEN
Agenus Botensilimab/Balstilimab Data Update in Sarcomas Selected for Oral Presentation at ESMO 2023
July 28, 2023
From Agenus Inc.
Via Business Wire
Tickers
AGEN
Agenus Expands Executive Leadership Team
July 20, 2023
From Agenus Inc.
Via Business Wire
Tickers
AGEN
Agenus Receives Fast Track Designation for Botensilimab and Balstilimab in Colorectal Cancer
April 17, 2023
From Agenus Inc.
Via Business Wire
Tickers
AGEN
From Agenus Inc.
Via Business Wire
Agenus’ Botensilimab in Combination with Balstilimab Shows 33% Durable Responses in Ovarian Cancer
March 27, 2023
From Agenus Inc.
Via Business Wire
Tickers
AGEN
Agenus Reports Fourth Quarter and Full Year 2022 Financial Results and Outlines 2023 Objectives
March 14, 2023
From Agenus Inc.
Via GlobeNewswire
Tickers
AGEN
Agenus Schedules Conference Call to Discuss the Company’s Minority Cash Holdings at SVB
March 11, 2023
From Agenus Inc.
Via GlobeNewswire
Tickers
AGEN
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2022 Financial Report
February 28, 2023
From Agenus Inc.
Via GlobeNewswire
Tickers
AGEN
Agenus to Participate in February Investor Conferences
January 26, 2023
From Agenus Inc.
Via GlobeNewswire
Tickers
AGEN
Agenus Data at CTOS 2022 Highlight Durable Clinical Responses of Botensilimab / Balstilimab Combination in Advanced Sarcoma
November 17, 2022
From Agenus Inc.
Via GlobeNewswire
Tickers
AGEN
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.